Copyright
©2014 Baishideng Publishing Group Co.
World J Cardiol. Mar 26, 2014; 6(3): 87-99
Published online Mar 26, 2014. doi: 10.4330/wjc.v6.i3.87
Published online Mar 26, 2014. doi: 10.4330/wjc.v6.i3.87
What do we know about PPCM? | What remains unknown about PPCM? |
Awareness is important for making an earlier diagnosis with less dysfunction | Actual “triggers” that initiate the process |
Hypertension in pregnancy increases risk for development of PPCM | Role of virus in pathogenesis |
Most serious complications can be decreased or avoided | Why higher incidence and more severe disease in those with African heritage |
Full recovery occurs more frequently than with any other cardiomyopathy | How important role cardiac autoantibodies play in pathogenesis |
Autoimmunity (or immune system dysfunction) a part of pathogenesis | The extent and details of genetic factors |
Inflammatory cardiomyopathy is common | Importance of the role of prolactin and prolactin inhibition treatment |
Higher incidence and more severe disease in those of African heritage | Importance of the role of sFLT1 in pathogenesis |
There can be a genetic predisposition | Why do some recovered have a relapse of heart failure with subsequent pregnancy |
Effective evidence-based treatment guidelines available | Role of micronutrients and trace metals in pathogenesis |
Most recovered do not have a relapse of heart failure in subsequent pregnancy | |
Occurs globally, but with geographic variations for incidence and unique characteristics |
- Citation: Fett JD. Peripartum cardiomyopathy: A puzzle closer to solution. World J Cardiol 2014; 6(3): 87-99
- URL: https://www.wjgnet.com/1949-8462/full/v6/i3/87.htm
- DOI: https://dx.doi.org/10.4330/wjc.v6.i3.87